⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for amd3100

Every month we try and update this database with for amd3100 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDSNCT00396968
Acute Myelogeno...
Myelodysplastic...
AMD3100
Allogeneic Stem...
18 Years - 60 YearsSanofi
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaNCT00903968
Multiple Myelom...
Plerixafor
bortezomib
Dexamethasone
18 Years - Dana-Farber Cancer Institute
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)NCT00444912
Non-Hodgkin Lym...
Hodgkin Disease
G-CSF plus pler...
G-CSF plus pler...
rituximab
18 Years - 70 YearsSanofi
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell CarcinomaNCT04058145
Head and Neck C...
AMD3100
Pembrolizumab
18 Years - Massachusetts General Hospital
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological MalignanciesNCT00914849
Hematologic Neo...
AMD3100
Leukopheresis
Stem cell trans...
18 Years - 65 YearsWashington University School of Medicine
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00694590
Chronic Lymphoc...
Small Lymphocyt...
plerixafor
18 Years - 80 YearsSanofi
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneNCT00395967
Multiple Myelom...
Lymphoma, Non-H...
G-CSF plus pler...
18 Years - 75 YearsSanofi
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological MalignanciesNCT00914849
Hematologic Neo...
AMD3100
Leukopheresis
Stem cell trans...
18 Years - 65 YearsWashington University School of Medicine
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute LeukemiaNCT01655875
Pediatric Acute...
Pediatric Acute...
AMD3100
2 Years - 22 YearsEmory University
Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT00694590
Chronic Lymphoc...
Small Lymphocyt...
plerixafor
18 Years - 80 YearsSanofi
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid LeukemiaNCT00512252
Leukemia, Myelo...
AMD3100
Mitoxantrone
Etoposide
Cytarabine
18 Years - 70 YearsWashington University School of Medicine
Long-Term Follow Up Study for AMD3100 PatientsNCT00476294
Myeloma
Telephone Quest...
18 Years - 78 YearsM.D. Anderson Cancer Center
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With LymphomaNCT00733824
Lymphoma, Non-H...
Hodgkin Disease
AMD3100
G-CSF
Apheresis
18 Years - 75 YearsWashington University School of Medicine
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFNCT00396266
Multiple Myelom...
Lymphoma, Non-H...
G-CSF Plus Pler...
18 Years - 70 YearsSanofi
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: